Usefulness of various antibiotics against Mycobacterium avium-intracellulare, measured by their mutant prevention concentration

International Journal of Antimicrobial Agents

Volumn 25, Issue 3, 2005, Pages 221-225

  Rodriguez J C ^a   Cebrian L ^a   Lopez M ^a   Ruiz, M ^a   Royo, G ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Fluoroquinolones; Linezolid; Macrolides; Mutant prevention concentration; Mycobacterium avium intracellulare

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; RIFABUTIN; RIFAMPICIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; IMMUNE SYSTEM; MUTANT PREVENTION CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; NONHUMAN; PRIORITY JOURNAL;

EID: 14344249145     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.09.018     Document Type: Article

References (36)

1. G. Sindelar, X. Zhao, and A. Liew Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria Antimicrob Agents Chemother 44 2000 3337 3343
2. Y. Dong, X. Zhao, B.N. Kreiswirth, and K. Drlica Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis Antimicrob Agents Chemother 44 2000 2581 2584
3. J.C. Rodriguez, M. Lopez, M. Ruiz, and G. Royo In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria Int J Antimicrob Agents 21 2003 585 588
4. J.C. Rodríguez, L. Cebrián, M. López, M. Ruiz, I. Jiménez, and G. Royo Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis J Antimicrob Chemother 53 2004 441 444
5. J.C. Rodríguez, L. Cebrián, M. López, M. Ruiz, and G. Royo Mutant prevention concentration: a new tool for deciding on treatment in nontuberculous mycobacterial infections Int J Antimicrob Agents 24 2004 352 356
6. Y. Kobashi, and T. Matsushima The effect of combined therapy according to the guidelines for the treatment of Mycobacterium avium complex pulmonary disease Intern Med 42 2003 670 675
7. S. Thiermann, J. Munzinger, and T. Bodmer Comparison of phenotypic and genotypic methods for the detection of clarithromycin resistance in Mycobacterium avium J Antimicrob Chemother 49 2002 679 681
8. H. Rinder Hetero-resistance: an under-recognised confounder in diagnosis and therapy? J Med Microbiol 50 2001 1018 1020
9. C.A. Peloquin Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes Clin Pharmacokinet 32 1997 132 144
10. J.A. Aberg, P.L. Williams, and T. Liu AIDS Clinical Trial Group 393 Study Team. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team J Infect Dis 187 2003 1046 1052
11. S.D. Shafran, L.D. Mashinter, and P. Phillips Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy Ann Intern Med 137 2002 734 737
12. S.V. Guide, and S.M. Holland Host susceptibility factors in mycobacterial infection. Genetics and body morphotype Infect Dis Clin North Am 16 2002 163 186
13. D. Saggese, G.C. Compadretti, and R. Burnelli Nontuberculous mycobacterial adenitis in children: diagnostic and therapeutic management Am J Otolaryngol 24 2003 79 84
14. Y. Shiraishi, Y. Nakajima, K. Takasuna, T. Hanaoka, N. Katsuragi, and H. Konno Surgery for Mycobacterium avium complex lung disease in the clarithromycin era Eur J Cardiothorac Surg 21 2002 314 318
15. H. Tomioka, C. Sano, K. Sato, and T. Shimizu Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex Int J Antimicrob Agents 19 2002 139 145
16. G. Apseloff, G. Foulds, L. LaBoy-Goral, S. Willavize, and J. Vincent Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers J Clin Pharmacol 38 1998 830 835
17. C.A. Benson, P.L. Williams, and D.L. Cohn Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team J Infect Dis 181 2000 1289 1297
18. M. Dunne, J. Fessel, and P. Kumar A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus Clin Infect Dis 31 2000 1245 1252
19. T.T. Ward, D. Rimland, C. Kauffman, M. Huycke, T.G. Evans, and L. Heifets Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium Clin Infect Dis 27 1998 1278 1285
20. P. Phillips, K. Chan, and R. Hogg Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program Clin Infect Dis 34 2002 371 378
21. D.E. Griffith, B.A. Brown, D.T. Murphy, W.M. Girard, L. Couch, and RJ. Wallace Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients J Infect Dis 178 1998 121 126
22. L.E. Bermudez, M. Petrofsky, P. Kolonoski, and L.S. Young Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy Antimicrob Agents Chemother 42 1998 180 183
23. R. Danesi, A. Lupetti, and C. Barbara Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg J Antimicrob Chemother 51 2003 939 945
24. J. McNabb, R.C. Owens, D. Xuan, R. Quintiliani, C.H. Nightingale, and D.P. Nicolau Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS Int J Antimicrob Agents 16 2000 37 43
25. K.A. Nash Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium Antimicrob Agents Chemother 45 2001 1607 1614
26. P. Keiser, N. Nassar, D. Skiest, S. Rademacher, and J.W. Smith A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection Int J STD AIDS 10 1999 791 794
27. L.E. Bermudez, C.B. Inderlied, and P. Kolonoski Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium Antimicrob Agents Chemother 45 2001 217 222
28. L.E. Bermudez, P. Kolonoski, M. Petrofsky, M. Wu, C.B. Inderlied, and L.S. Young Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease J Infect Dis 15 187 2003 1977 1980
29. R. Gozalbes, M. Brun-Pascaud, and R. Garcia-Domenech Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening Antimicrob Agents Chemother 4 2000 2764 2770
30. J. Zhou, Y. Dong, and X. Zhao Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations J Infect Dis 182 2000 517 525
31. J.C. Rodríguez, M. Ruiz, M. López, and G. Royo In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis Int J Antimicrob Agents 20 2002 464 467
32. E.C. Nannini, M. Keating, P. Binstock, G. Samonis, and D.P. Kontoyiannis Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine J Infect 44 2002 201 203
33. H. Furrer Cohort study. Management of opportunistic infection prophylaxis in the highly active antiretroviral therapy era Curr Infect Dis Rep 4 2002 161 174
34. S.E. Cohn, E. Kammann, P. Williams, J.S. Currier, and M.A. Chesney Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency Syndrome Clin Infect Dis 34 2002 1129 1136
35. M.L. Heginbothom The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment Int J Tuberc Lung Dis 5 2001 539 545
36. L.E. Bermudez, K. Nash, M. Petrofsky, L.S. Young, and C.B. Inderlied Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice Antimicrob Agents Chemother 44 2000 2619 2622